TB Alliance Advances Next-generation TB Drug Candidate into Clinical Testing
TB Alliance has announced the start of the first human trial of a new tuberculosis (TB) drug candidate, designated TBA-354.
TB Alliance has announced the start of the first human trial of a new tuberculosis (TB) drug candidate, designated TBA-354.
A promising new tuberculosis (TB) drug regimen, which could improve the treatment of drug sensitive TB and multi-drug resistant (MDR-)
TB Alliance, an international not-for-profit organization with the mission of developing improved tuberculosis (TB) treatments, announced the appointment of Mario
OPBIO Factory Co., Ltd. (OPBIO) has signed a research agreement with the Global Alliance for TB Drug Development (TB Alliance).
TB Alliance has launched a Phase 2B trial that will test the safety and effectiveness of a novel regimen with
TB Alliance announced today that pretomanid (pronounced: pree TOH mah nid) will be the generic, nonproprietary name for its novel
· REMoxTB confirmed the safety of moxifloxacin and its effect in killing TB; results pave way for further study of
Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance) for compounds
TB Alliance, a not-for-profit with the mission of discovering and developing better, faster and affordable treatments, announced the appointment of
TB Alliance, a not-for-profit organization with the mission of developing better, faster and affordable treatments for tuberculosis (TB), announced the